refinedscience.com

What It Is

RefinedScience is a precision oncology evidence platform for pharmaceutical and biotech companies, backed by a joint venture between CU Anschutz and UCHealth. It is not a typical general-purpose SaaS product. Instead, it combines longitudinal clinical data, EHR records, biobanks, single-cell omics, real patient-derived tissue models, and AI analytics tools to improve target validation, patient selection, and clinical execution quality in oncology drug development.

Core Capabilities

The platform focuses on four main areas: deep clinical and multimodal data, AI analytics, biological validation, and an interdisciplinary expert team. Its proprietary tools include scExploreR, Marksman, Scout, and PULSE, and it has generated 1000+ AI reports and 700+ functional experiments. Its service workflow spans target discovery in the discovery stage, antibody/small-molecule target validation, resistance mechanisms, combination therapies, and primary tissue testing in translational validation, as well as patient stratification, biomarkers, external data controls, synthetic trial simulation, and CDx discovery in clinical development. AML ADC Discovery is one of its flagship programs, emphasizing target screening at the tumor-initiating-cell level.

Pricing and Delivery

The website does not disclose plans, pricing, a free tier, or trials. Its collaboration model appears closer to project-based or strategic partnerships: each engagement is customized around a pharmaceutical company’s specific biological questions rather than a fixed service catalog. For buyers, this means the work can be closely aligned with pipeline needs, but budget, timeline, and delivery boundaries need to be confirmed through commercial discussions.

Pros and Cons

Its strengths come from its institutional backing, which provides access to clinical data, real patient tissues, and samples. In AML in particular, it discloses 300+ patient datasets, a 41TB single-cell database, and the Verily Exchange dataset. Its case studies include Phase II clinical support, work related to FDA breakthrough therapy applications, and translational research for major pharmaceutical companies. The limitations are the lack of standard SaaS information: it does not disclose account permissions, deployment options, APIs, developer documentation, compliance certifications, or payment methods. Its applicability is also mainly concentrated in oncology and selected indications.

Who It’s For and Access from China

It is best suited for pharmaceutical companies, ADC platform companies, and biotech firms with programs in AML, MDS, PDAC, ovarian cancer, esophageal cancer, GBM, or DLBCL, especially teams that need target validation, patient enrichment, companion diagnostics, or real-world external controls. Access from China cannot be determined from the available text, and payment methods are not disclosed. Domestic teams considering procurement should carefully assess cross-border data compliance, contract research boundaries, and alternative providers such as Tempus, Flatiron, ConcertAI, or Chinese precision medicine / real-world data platforms.